Antivascular Endothelial Growth Factor as an Approach for Macular Edema
Macular edema is an abnormal thickening of the macula associated with the accumulation of excess fluid in the extracellular space of the neurosensory retina. The following chapter looks at the basic pathomechanisms of macular edema as well as major pathologic conditions leading to it: special focus...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Buchkapitel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 122 |
|---|---|
| container_issue | |
| container_start_page | 111 |
| container_title | |
| container_volume | 46 |
| creator | Buchholz, P.M. Buchholz, A.P. Augustin, A.J. |
| description | Macular edema is an abnormal thickening of the macula associated with the accumulation of excess fluid in the extracellular space of the neurosensory retina. The following chapter looks at the basic pathomechanisms of macular edema as well as major pathologic conditions leading to it: special focus is on diabetic retinopathy, retinal venous occlusions and a number of inflammatory disorders. Currently available data on up-to-date pharmacologic treatment options such as steroids and anti-VEGF compounds is presented and discussed. |
| doi_str_mv | 10.1159/000320014 |
| format | Book Chapter |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_20703037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EBC3016390_85_122</sourcerecordid><originalsourceid>FETCH-LOGICAL-k350t-8c47b3b8f97bb31cbfaeeff46a452199eeed3ff89e4eeaa9fd4b61200fd76ad73</originalsourceid><addsrcrecordid>eNpdkU9v00AQxRcKtKHkwBdA7qknl9md_eM9RlWbViriQs_WrD1LrDh22HWK-PZYJFx6Gmnm_Z5m3gjxWcKNlMZ_BQBUAFK_ER-xAmO8QZBvxUJaq0rlPJyJpXfVaaa8eicWoAyU6Iz8IBbWatTWWLgQy5y7AKAVOmf0ubhQ4AAB3UKsV8PUvVBuDj2l4m5ox2nDfUd9sU7j72lT3FMzjamgXNBQrPb7NFKzKeLc-kYnqOUdfRLvI_WZl6d6KZ7v737cPpRP39ePt6uncosGprJqtAsYquhdCCibEIk5Rm1JGyW9Z-YWY6w8a2YiH1sdrJxziK2z1Dq8FNdH33mRXwfOU73rcsN9TwOPh1w7XXkt0elZ-eWkPIQdt_U-dTtKf-r_t88CfGXFYRy3DQ9Tor7Z0H7ilOs5dYse6srUUqmZujpSW0o_OR2ZnDl1PGv_fQz_AtGDf1U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>book_chapter</recordtype><pqid>EBC3016390_85_122</pqid></control><display><type>book_chapter</type><title>Antivascular Endothelial Growth Factor as an Approach for Macular Edema</title><source>MEDLINE</source><source>Karger Book Series</source><creator>Buchholz, P.M. ; Buchholz, A.P. ; Augustin, A.J.</creator><contributor>Bandello F ; Battaglia Parodi M ; Augustin, A. J ; Schmidt-Erfurth, U ; Schlingemann, R. O ; Iacono, P ; Verbraak, F. D ; Battaglia Parodi, M</contributor><creatorcontrib>Buchholz, P.M. ; Buchholz, A.P. ; Augustin, A.J. ; Bandello F ; Battaglia Parodi M ; Augustin, A. J ; Schmidt-Erfurth, U ; Schlingemann, R. O ; Iacono, P ; Verbraak, F. D ; Battaglia Parodi, M</creatorcontrib><description>Macular edema is an abnormal thickening of the macula associated with the accumulation of excess fluid in the extracellular space of the neurosensory retina. The following chapter looks at the basic pathomechanisms of macular edema as well as major pathologic conditions leading to it: special focus is on diabetic retinopathy, retinal venous occlusions and a number of inflammatory disorders. Currently available data on up-to-date pharmacologic treatment options such as steroids and anti-VEGF compounds is presented and discussed.</description><identifier>ISSN: 0250-3751</identifier><identifier>ISBN: 9783805595292</identifier><identifier>ISBN: 3805595298</identifier><identifier>EISSN: 1662-2790</identifier><identifier>EISBN: 3805595301</identifier><identifier>EISBN: 9783805595308</identifier><identifier>DOI: 10.1159/000320014</identifier><identifier>OCLC: 664346560</identifier><identifier>PMID: 20703037</identifier><identifier>LCCallNum: RE720.A58 2010</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Cataract - complications ; Cataract Extraction - adverse effects ; Chapter ; Diabetic Retinopathy - complications ; Fluorescein Angiography ; Humans ; Macular Edema - diagnosis ; Macular Edema - drug therapy ; Macular Edema - etiology ; Macular Edema - physiopathology ; Ophthalmology ; Ranibizumab ; Retinal Vein Occlusion - complications ; Steroids - therapeutic use ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><ispartof>Anti-VEGF, 2010, Vol.46, p.111-122</ispartof><rights>2010 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><relation>Anti-VEGF</relation></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttps://ebookcentral.proquest.com/covers/3016390-l.jpg</thumbnail><link.rule.ids>314,779,780,784,793,26080,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20703037$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Bandello F</contributor><contributor>Battaglia Parodi M</contributor><contributor>Augustin, A. J</contributor><contributor>Schmidt-Erfurth, U</contributor><contributor>Schlingemann, R. O</contributor><contributor>Iacono, P</contributor><contributor>Verbraak, F. D</contributor><contributor>Battaglia Parodi, M</contributor><creatorcontrib>Buchholz, P.M.</creatorcontrib><creatorcontrib>Buchholz, A.P.</creatorcontrib><creatorcontrib>Augustin, A.J.</creatorcontrib><title>Antivascular Endothelial Growth Factor as an Approach for Macular Edema</title><title>Anti-VEGF</title><addtitle>Dev Ophthalmol</addtitle><description>Macular edema is an abnormal thickening of the macula associated with the accumulation of excess fluid in the extracellular space of the neurosensory retina. The following chapter looks at the basic pathomechanisms of macular edema as well as major pathologic conditions leading to it: special focus is on diabetic retinopathy, retinal venous occlusions and a number of inflammatory disorders. Currently available data on up-to-date pharmacologic treatment options such as steroids and anti-VEGF compounds is presented and discussed.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Bevacizumab</subject><subject>Cataract - complications</subject><subject>Cataract Extraction - adverse effects</subject><subject>Chapter</subject><subject>Diabetic Retinopathy - complications</subject><subject>Fluorescein Angiography</subject><subject>Humans</subject><subject>Macular Edema - diagnosis</subject><subject>Macular Edema - drug therapy</subject><subject>Macular Edema - etiology</subject><subject>Macular Edema - physiopathology</subject><subject>Ophthalmology</subject><subject>Ranibizumab</subject><subject>Retinal Vein Occlusion - complications</subject><subject>Steroids - therapeutic use</subject><subject>Tomography, Optical Coherence</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><issn>0250-3751</issn><issn>1662-2790</issn><isbn>9783805595292</isbn><isbn>3805595298</isbn><isbn>3805595301</isbn><isbn>9783805595308</isbn><fulltext>true</fulltext><rsrctype>book_chapter</rsrctype><creationdate>2010</creationdate><recordtype>book_chapter</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU9v00AQxRcKtKHkwBdA7qknl9md_eM9RlWbViriQs_WrD1LrDh22HWK-PZYJFx6Gmnm_Z5m3gjxWcKNlMZ_BQBUAFK_ER-xAmO8QZBvxUJaq0rlPJyJpXfVaaa8eicWoAyU6Iz8IBbWatTWWLgQy5y7AKAVOmf0ubhQ4AAB3UKsV8PUvVBuDj2l4m5ox2nDfUd9sU7j72lT3FMzjamgXNBQrPb7NFKzKeLc-kYnqOUdfRLvI_WZl6d6KZ7v737cPpRP39ePt6uncosGprJqtAsYquhdCCibEIk5Rm1JGyW9Z-YWY6w8a2YiH1sdrJxziK2z1Dq8FNdH33mRXwfOU73rcsN9TwOPh1w7XXkt0elZ-eWkPIQdt_U-dTtKf-r_t88CfGXFYRy3DQ9Tor7Z0H7ilOs5dYse6srUUqmZujpSW0o_OR2ZnDl1PGv_fQz_AtGDf1U</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Buchholz, P.M.</creator><creator>Buchholz, A.P.</creator><creator>Augustin, A.J.</creator><general>S. Karger AG</general><scope>FFUUA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20100101</creationdate><title>Antivascular Endothelial Growth Factor as an Approach for Macular Edema</title><author>Buchholz, P.M. ; Buchholz, A.P. ; Augustin, A.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-k350t-8c47b3b8f97bb31cbfaeeff46a452199eeed3ff89e4eeaa9fd4b61200fd76ad73</frbrgroupid><rsrctype>book_chapters</rsrctype><prefilter>book_chapters</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Bevacizumab</topic><topic>Cataract - complications</topic><topic>Cataract Extraction - adverse effects</topic><topic>Chapter</topic><topic>Diabetic Retinopathy - complications</topic><topic>Fluorescein Angiography</topic><topic>Humans</topic><topic>Macular Edema - diagnosis</topic><topic>Macular Edema - drug therapy</topic><topic>Macular Edema - etiology</topic><topic>Macular Edema - physiopathology</topic><topic>Ophthalmology</topic><topic>Ranibizumab</topic><topic>Retinal Vein Occlusion - complications</topic><topic>Steroids - therapeutic use</topic><topic>Tomography, Optical Coherence</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buchholz, P.M.</creatorcontrib><creatorcontrib>Buchholz, A.P.</creatorcontrib><creatorcontrib>Augustin, A.J.</creatorcontrib><collection>ProQuest Ebook Central - Book Chapters - Demo use only</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buchholz, P.M.</au><au>Buchholz, A.P.</au><au>Augustin, A.J.</au><au>Bandello F</au><au>Battaglia Parodi M</au><au>Augustin, A. J</au><au>Schmidt-Erfurth, U</au><au>Schlingemann, R. O</au><au>Iacono, P</au><au>Verbraak, F. D</au><au>Battaglia Parodi, M</au><format>book</format><genre>bookitem</genre><ristype>CHAP</ristype><atitle>Antivascular Endothelial Growth Factor as an Approach for Macular Edema</atitle><btitle>Anti-VEGF</btitle><addtitle>Dev Ophthalmol</addtitle><seriestitle>Anti-VEGF</seriestitle><date>2010-01-01</date><risdate>2010</risdate><volume>46</volume><spage>111</spage><epage>122</epage><pages>111-122</pages><issn>0250-3751</issn><eissn>1662-2790</eissn><isbn>9783805595292</isbn><isbn>3805595298</isbn><eisbn>3805595301</eisbn><eisbn>9783805595308</eisbn><abstract>Macular edema is an abnormal thickening of the macula associated with the accumulation of excess fluid in the extracellular space of the neurosensory retina. The following chapter looks at the basic pathomechanisms of macular edema as well as major pathologic conditions leading to it: special focus is on diabetic retinopathy, retinal venous occlusions and a number of inflammatory disorders. Currently available data on up-to-date pharmacologic treatment options such as steroids and anti-VEGF compounds is presented and discussed.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>20703037</pmid><doi>10.1159/000320014</doi><oclcid>664346560</oclcid><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-3751 |
| ispartof | Anti-VEGF, 2010, Vol.46, p.111-122 |
| issn | 0250-3751 1662-2790 |
| language | eng |
| recordid | cdi_pubmed_primary_20703037 |
| source | MEDLINE; Karger Book Series |
| subjects | Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bevacizumab Cataract - complications Cataract Extraction - adverse effects Chapter Diabetic Retinopathy - complications Fluorescein Angiography Humans Macular Edema - diagnosis Macular Edema - drug therapy Macular Edema - etiology Macular Edema - physiopathology Ophthalmology Ranibizumab Retinal Vein Occlusion - complications Steroids - therapeutic use Tomography, Optical Coherence Vascular Endothelial Growth Factor A - antagonists & inhibitors |
| title | Antivascular Endothelial Growth Factor as an Approach for Macular Edema |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T13%3A22%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=bookitem&rft.atitle=Antivascular%20Endothelial%20Growth%20Factor%20as%20an%20Approach%20for%20Macular%20Edema&rft.btitle=Anti-VEGF&rft.au=Buchholz,%20P.M.&rft.date=2010-01-01&rft.volume=46&rft.spage=111&rft.epage=122&rft.pages=111-122&rft.issn=0250-3751&rft.eissn=1662-2790&rft.isbn=9783805595292&rft.isbn_list=3805595298&rft_id=info:doi/10.1159/000320014&rft_dat=%3Cproquest_pubme%3EEBC3016390_85_122%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&rft.eisbn=3805595301&rft.eisbn_list=9783805595308&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=EBC3016390_85_122&rft_id=info:pmid/20703037&rfr_iscdi=true |